Indeed, allele burden of JAK2 V617F is generally low in ET (< 25%), high in PV (> 50%), frequently high in PMF and close to 100% in post-PV/ET myelofibrosis 34. This evidence concerns the gene JAK2 and essential thrombocythemia.